How Will Abenomics Force This Stock to Evolve?
We expect a progressive change in this insurer's product mix and investment strategies.
Japanese investors are used to disappointment, given the economy's stagnation over the past two or three decades. The introduction of Prime Minister Shinzo Abe's economic reform plan in late 2012 represented one of the best hopes for breaking the economy out of its long-standing slump, but the situation remains fragile, complex, and highly uncertain. One thing remains clear: Given a rapidly aging (and shrinking) population in Japan, coupled with a cutback in national health-care coverage, Aflac (AFL) has a unique long-term growth opportunity as the leading provider of voluntary medical coverage. However, the impact of Abenomics and the corresponding declines in bond yields and the yen complicate this attractive picture for one of our favorite insurers, as we anticipate lower insurance sales and investment income in the near term. As a result, it is critical that investors understand how Aflac will navigate this challenging environment to fully capture the tremendous growth in front of it.
At a minimum, we believe Aflac's product and investment strategies will have to evolve. At a product level, the changes include a heavier reliance on cancer and medical policies and a corresponding reduction in the life insurance business. For Aflac's investments, we expect to see a higher allocation for U.S.-denominated bonds, versus its traditional focus on Japanese government bonds. Overall, we think Aflac offers a high-quality opportunity to play a powerful long-term secular trend in a country where strong and investable companies are few and far between. We would be avid buyers at a discount to our fair value estimate.
Vincent Lui does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.